Industry Funding Opportunities

For all InPart Funding Listings please Contact Karla Zepeda

One.Five - Biomaterials for High-Barrier Heat-Sealable Paper Coatings 02.06.2023

InPart Funding
Materials

Deadline: February 6th 2023 one.five is seeking biodegradable and bio-based materials for high-barrier or other functional (e.g., heating-sealing, food contact safe) paper coatings. This includes single substance as well as composites and multi-layer systems. Natural polymers directly extracted from biomass without further chemical modification that can be applied to flexible or rigid paper-based food packaging are of particular interest.

Open One.Five - Biomaterials for High-Barrier Heat-Sealable Paper Coatings 02.06.2023 PDF

Santen - Novel Druggable Targets and Drug Delivery Systems in Ophthamology 01.23.2023

InPart Funding
Drug Delivery

Deadline: January 23rd 2022 Santen, a Japanese pharmaceutical company leading in transformative solutions in both common and rare ophthalmological conditions, is seeking new druggable targets and ocular drug delivery systems, including both the front and the back of the eye. Novel Druggable Targets: Diseases of interest include presbyopia, myopia, Fuchs dystrophy, new targets in glaucoma (not just for intraocular pressure lowering), retinitis pigmentosa, dry eye disease, dry age-related macular degeneration (AMD), geographic atrophy and seasonal allergic conjunctivitis. Open to different modalities including small molecules, biologics, gene therapy, cell therapy and drug repurposing. Patient biomarkers related to the above mentioned diseases

Open Santen - Novel Druggable Targets and Drug Delivery Systems in Ophthamology 01.23.2023 PDF

Anonymous - Cell and Gene-based Therapy for Canine Diabetes

InPart Funding
Therapeutics and Vaccines

Deadline: January 30th 2023 A global animal health company is seeking research and technologies related to cell and gene-based treatments for canine type I and II diabetes. The team are looking to develop novel treatments for dogs, but research in humans is of interest at this stage. The research should relate to simulating insulin-producing cells in order to stabilise and maintain appropriate blood glucose levels. Treatments should aim to stabilise glucose for at least 3-6 months, preferably more. Our client is particularly interested in validated research ready for further development e.g. manufacturing or clinical testing.

Open Anonymous - Cell and Gene-based Therapy for Canine Diabetes PDF